Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Recent & Breaking News (NDAQ:AVXL)

Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X – Autism-Related Disorders

GlobeNewswire June 6, 2016

Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome

GlobeNewswire May 20, 2016

Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms

GlobeNewswire May 18, 2016

Anavex Reports Fiscal Second Quarter 2016 Financial Results

GlobeNewswire May 11, 2016

Aclaris Therapeutics Reports First Quarter 2016 Financial Results

GlobeNewswire May 11, 2016

U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia

GlobeNewswire April 8, 2016

Anavex Presents New Data on Preclinical Development of ANAVEX 3-71

GlobeNewswire March 14, 2016

Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference

GlobeNewswire March 10, 2016

Scott + Scott, LLP Reminds Investors that Monday, Feb. 29, 2016 is the Last Day to file Lead Plaintiff Papers in the Anavex Life Sciences (AVXL) Securities Case

Business Wire February 26, 2016

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Anavex Life Sciences Corp of Class Action Lawsuit and Upcoming Deadline - AVXL

Accesswire February 26, 2016

Scott + Scott, LLP Reminds Investors of Monday, Feb. 29, 2016 Deadline in Anavex Life Sciences (AVXL) Securities Case

Business Wire February 25, 2016

Anavex Presents Preclinical Results of ANAVEX 2-73 in Rett Syndrome

GlobeNewswire February 25, 2016

Scott + Scott, LLP Reminds Investors of Deadline to File Lead Plaintiff Papers in Anavex Life Sciences (AVXL) Securities Lawsuit

Business Wire February 23, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Anavex Life Sciences Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 29, 2016 - AVXL

PR Newswire February 23, 2016

February 29 Deadline Alert: Law Offices of Howard G. Smith Reminds Anavex Life Sciences Corp. Investors of Upcoming Lead Plaintiff Deadline

Business Wire February 22, 2016

IMPORTANT SHAREHOLDER ALERT: Scott + Scott, LLP Investigating Anavex Life Sciences (AVXL) for Possible Securities Fraud

Business Wire February 22, 2016

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Anavex Life Sciences Corp. and a Lead Plaintiff Deadline of February 29, 2016 - AVXL

GlobeNewswire February 19, 2016

DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Anavex Life Sciences Corp. of Upcoming Deadline -- AVXL

GlobeNewswire February 19, 2016

SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Anavex Life Sciences Corp. And Reminds Investors With Losses In Excess of $250,000 To Contact The Firm

Business Wire February 17, 2016

ANAVEX 2-73 Preclinical Data in New Indication to be Presented at ACTRIMS 2016

Press Releases February 17, 2016